A Case of Management for Advanced Hepatocellular Carcinoma with Extrahepatic Metastasis by Autologous Natural Killer Cells Combined with Immune Checkpoint Inhibitor
- Author:
Ara WOO
1
;
Eun Ju KIM
;
Sun Young SHIN
;
Hong Jae JEON
;
Hana PARK
;
Young Eun CHON
;
Yun Bin LEE
;
Seong Gyu HWANG
;
Kyu Sung RIM
;
Joo Ho LEE
Author Information
- Publication Type:Case Report
- Keywords: Hepatocellular carcinoma; Immunotherapy; Natural killer cells; Programmed cell death 1 protein
- MeSH: Antibodies, Blocking; Carcinoma, Hepatocellular; Cell Death; Cytokine-Induced Killer Cells; Disease Progression; Humans; Immunotherapy; Immunotherapy, Adoptive; Killer Cells, Natural; Liver; Lymphocytes; Neoplasm Metastasis; Prognosis; Programmed Cell Death 1 Receptor; T-Lymphocytes, Cytotoxic
- From:Journal of Liver Cancer 2018;18(1):67-74
- CountryRepublic of Korea
- Language:Korean
- Abstract: Hepatocellular carcinoma (HCC) has extremely poor prognosis. Immunotherapy has emerged as a new treatment for a number of cancers. Adoptive immunotherapy is one of the important cancer immunotherapy, which relies on the various lymphocytes including cytotoxic T lymphocytes, natural killer (NK) and cytokine induced killer cells. Also, there has been advance in techniques of NK cell activation to more effectively kill the cancer cells. Of note, recently the blocking antibodies targeting programmed cell death protein 1 (PD-1) have shown promising results in diverse cancers including HCC. We report our recent experience of a patient accompanying advanced HCC with extrahepatic metastases. Disease progression had occurred after sorafenib administration, while the patient showed local tumor control and tumor marker decrease by NK cell immunotherapy combined with PD-1 inhibitor therapy. Though, there was no definite survival advantage due to impaired liver function, which might be caused by treatment related toxicities as well as cancer progression.